Search by property
From Bioblast
This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.
List of results
- Axelrod 2019 Abstract IOC141 + (Current pharmacologic strategies for the t … Current pharmacologic strategies for the treatment of obesity remain ineffective at achieving long-term weight control. This is due, in part, to difficulties in identifying tolerable and efficacious small molecules and biologics capable of regulating systemic nutrient homeostasis. Mitochondria present a unique opportunity for drug targeting by regulating systemic nutrient flux across tissues and cell types. However, unfavorable pharmacokinetic properties, off-target effects, and poor tolerability have limited clinical application. Herein, we evaluated the effects of BAM15 on body weight regulation and skeletal muscle mitochondrial function. 16 (n=8 per group) diet induced obese (DIO) male C57BL/6J mice were randomized to 3 weeks of high fat diet (HFD) or BAM15 (HFD + 0.01% w/w BAM15). After 3 weeks, mixed gastrocnemius muscle was harvested after euthanasia and assessed for oxidative phosphorylation (OXPHOS) and electron transport (ETC) capacity [1], as well as [1-14C]palmitate oxidation ]2], as described previously. Mice treated chronically with BAM15 were resistance to dietary weight gain, attributable to reductions in fat accrual. BAM15 treated animals displayed increased skeletal muscle fatty acid oxidation. However, OXPHOS and ETC capacity with glucose or fatty acid substrates remained unchanged between control and BAM15 treated animals. We conclude that BAM15 is tolerable and efficacious small molecule for the treatment of obesity. Importantly, chronic administration of BAM15 does not result in mitochondrial fatigue or dysfunction, warranting further investigation into pre-clinical efficacy and tolerability.to pre-clinical efficacy and tolerability.)
